Drug Profile
Vopratelimab - Concentra Biosciences
Alternative Names: ICOS agonist monoclonal antibody; JTX-2011Latest Information Update: 15 May 2023
Price :
$50
*
At a glance
- Originator Jounce Therapeutics
- Developer Concentra Biosciences
- Class Antineoplastics; Cell therapies; Immunotherapies; Monoclonal antibodies; T lymphocyte cell therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Inducible T-cell co-stimulator protein agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer; Solid tumours; Urogenital cancer
Most Recent Events
- 01 May 2023 Jounce Therapeutics has been acquired and merged into Concentra Biosciences
- 31 Jan 2023 Jounce Therapeutics completes a phase I/II trial in Solid tumours (Monotherapy, Combination therapy, Second-line therapy, Metastatic disease, Late-stage disease) in USA (IV) (NCT04319224)
- 20 Sep 2022 Jounce Therapeutics completes the phase II EMERGE trial in Non-small cell lung cancer and Urogenital cancer (Combination therapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA and Canada (IV) (NCT03989362)